MRNA HIV vaccines enter human trials in south africa

NCT ID NCT06694753

Ongoing ⭐️ VACCINE ⭐️ Sponsor: International AIDS Vaccine Initiative Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-stage trial tests three experimental mRNA vaccines designed to train the immune system to fight HIV. The study involves 96 healthy adults without HIV in South Africa. Researchers will check for side effects and measure whether the vaccines trigger specific immune cells that could neutralize the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA vaccines encoding HIV immunogens (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 gp151)
What this could lead to: If successful, this could point toward a safe and effective HIV vaccine, potentially preventing infection.
What could go wrong: This is an early phase 1 trial with only 96 participants, so it may not prove effective. The vaccines may cause side effects or fail to generate strong immune responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

CAPRISA eThekwini CRS

Durban, KwaZulu-Natal, 4001, South Africa
Desmond Tutu Health Foundation Emavundleni CRS

Cape Town, Western Cape, 7750, South Africa
Desmond Tutu Health Foundation- Groote Schuur Hospital/J52

Cape Town, Western Cape, 7925, South Africa
Isipingo CRS

Isipingo, KwaZulu-Natal, 4110, South Africa
Perinatal HIV Research Unit (PHRU)

Soweto, Gauteng, 1862, South Africa
Setshaba Research Centre CRS

Soshanguve, Gauteng, 0152, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.